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1. INTRODUCTION 
  
Pharmaceutical analytical chemistry is concerned with the identification of a 
substance, the elucidation of its structure and quantitative analysis of its composition. 
It is an interdisciplinary branch of science which deals with various disciplines of 
chemistry such as inorganic, organic, physical, industrial and biochemistry. It also 
finds extensive application in environmental science, agricultural science and clinical 
chemistry, solid state research and electronics, oceanography, forensic science and 
space research. The scope of analytical chemistry is very broad and embraces a wide 
range of manual, chemical and instrumental techniques. [1] 
 
Pharmaceutical analyst in research and development (R&D) of pharma 
industry plays a very comprehensive role in new drug development and follow up 
activities to ensure that, a new drug product meets the established standards, its 
stability and continued to meet quality throughout its shelf life. 
 
The different activity of R&D includes drug development, (synthesis and 
manufacture), formulation, clinical trials, evaluation and finally launching i.e., 
finished products. Closely associated with these processes are regulatory and quality 
assurance functions. 
 
1.1   CLASSIFICATION OF ANALYTICAL TECHNIQUES 
 
The discipline involves qualitative analysis and quantitative analysis 
¾ Qualitative Analysis: deals with identification of the substance [2] 
¾ Quantitative analysis: deals with  determination of  amount of  constituent 
present. 
 
The applied science of analytical chemistry is instrumental analysis, which 
involves the study of theoretical principle of various instrumental methods. 
 
In this the physical property of a substance is measured to determine its 
chemical composition. These methods save the time and avoid chemical separation 
and give increased accurate results. 
 The instrumental methods can be categorized into five techniques are 
tabulated in table no. 1 as follows [3] 
 
Table No: 1 Classification of instrumental analytical methods 
Spectro 
photometric 
Techniques 
Electro- 
Chemical 
Techniques 
Chromato 
graphic 
Techniques
Miscellaneous 
Techniques 
Hyphenated 
Techniques 
Colorimetry Conductometry HPLC Thermal 
analysis 
(TGA & DSC) 
LC-MS 
UV-Visible 
spectroscopy 
Potentiometry UPLC GC-MS 
Fluorescence and 
phosphorescence 
spectroscopy 
Coulometry GC  GC-IR 
Atomic 
spectroscopy 
Voltammetry TLC  LC-MS/MS 
IR spectroscopy 
Electro-
gravimetry 
HPTLC  LC-NMR 
X- ray radiation  SFC  ICP-MS 
Mass spectroscopy  TLC  GC-ICP-MS 
NMR spectroscopy    LC-NMR 
Turbidimetry and 
Nephelometry 
    
Electron spin 
resonance 
spectroscopy 
    
 
 
 
 
 
1.2   CHROMATOGRAPHY 
Chromatography is a technique in which solutes are resolved by differential 
rates of elution as they pass through a chromatographic column. Chromatography is 
essentially a group of techniques for the separation of the compounds of mixtures by 
their continuous distribution between two phases, one of which moves relative to the 
other. [4] 
 
History:  
Many publications have discussed or detailed the history and development of 
chromatography. Table No.2 lists the chronological order of the events that are the 
most notable in the development of the present state of the field. Since the various 
types of chromatography (liquid, gas, paper, thin-layer, ion exchange, supercritical 
fluid, and electrophoresis) have many features in common, they must all be 
considered in development of the field. [5]  
 
Table No: 2 Development of the chromatography 
Year Scientist Research findings 
1834 Runge .F.F 
Used unglazed paper and / or pieces of cloth 
for spot testing dye mixtures and plant 
extracts 
1850 Runge .F.F Separated salt solutions on paper 
1868 Goppelsroeder,F. 
Introduced paper strip (capillary analysis) 
analysis of dyes, hydrocarbons, milk, beer, 
colloids, drinking and mineral water, plant 
and animal pigments 
1906-1907 Twsett,M. 
Separated chloroplast pigment on CaCO3 
solid phase and petroleum ether liquid phase 
1931 Kuhn,R.et.al 
 
Introduced liquid-solid chromatography for 
separating egg yolk xanthophylls 
1940 Wilson,J.N 
Wrote first theoretical paper on 
chromatography: assumed complete 
equilibration and linear sorption isotherms, 
qualitatively defined diffusion, rate of 
adsorption, and isotherm non linearity 
1941 Tiselius,A. 
Developed liquid chromatography and 
pointed out frontal analysis, elution analysis, 
and displacement development 
1944 
Consden, 
R.,Gordon,A.H., 
& Martin, A.J.P 
Developed paper chromatography 
1946 Claesson,S. 
Developed liquid-solid chromatography with 
frontal and displacement development 
analysis 
1951 Cremer,E. Introduced gas-solid  chromatography 
1952 
James,A.T.,and 
Martin,A.J.P. 
Introduced gas-liquid  chromatography 
1957 Golay,M 
Reported the development of open tubular 
columns 
 
 
High Performance Liquid Chromatography 
High performance liquid chromatography is the fastest growing analytical 
technique for the analysis of the drugs. Its simplicity, high specificity and wide range 
of sensitivity make it ideal for an analysis of many drugs in both dosage forms and 
biological fluids. HPLC was developed in the late 1960s and 1970s. Today it is 
widely accepted separation technique for both sample analysis and purification in 
variety of areas. The successful use of liquid chromatography requires the right 
combination of a variety of operating conditions such as the type of, 
• Column packing. 
• Mobile phase and its flow rate. 
• Column length and diameter. 
• Column temperature and sample size. 
General uses of HPLC 
1. Separation of wide variety of compounds, organic, inorganic and 
 biological compounds, polymers, chiral compounds, thermally liable    
compounds and small ions to macro molecules. 
2. Analysis of impurities. 
3. Analysis of both volatile and nonvolatile compounds. 
4. Determination of neutral ionic or zwitter ionic molecules. 
5. Isolation and purification of compounds. 
6. Ultra trace to preparative and process scale separations. 
7. Qualitative and quantitative method.[6] 
 
Guide to Liquid Chromatography Mode Selection 
Selection of chromatography mode is based upon the analyte polarity, 
solubility and ionic nature. [7] A guide to liquid chromatography mode selection is 
represented in fig no: 1 
                                                        Low polarity 
  Non-ionic 
  
                                High polarity 
         MW <2000 
 
                                                          Acidic    
 Ionic  
                        Basic  
Sample 
  
 
                                       Water soluble 
 
  
         MW >2000            Water insoluble  
                                          
 
Fig. No: 1 Guide to Liquid Chromatography Mode Selection 
Reverse Phase HPLC 
Reverse phase, aqueous mobile phase 
Liquid, solid or bonded phase 
Anion exchange/ion pair 
Cation exchange/ion pair 
Size exclusion, aqueous mobile phase 
Size exclusion, non‐aqueous mobile 
phase.
Reverse phase chromatography refers to the use of a polar mobile phase with 
the non-polar stationary phase in contrast to normal phase chromatography where a 
polar stationary phase is employed with a non-polar mobile phase. [8] The figure No. 2 
and 3 shows the HPLC system and its various components. 
 
 
Fig.No: 2 High Performance Liquid Chromatography 
 
 
 
 
 
Fig.No: 3 Block diagram showing the components of an HPLC instrument 
 
 
Reverse phase column packing 
The liquid-liquid partition chromatography uses a stationary phase consisting 
of liquid layer adsorbed to a surface of silica or alumina. In case of bonded phase or 
reverse phase HPLC uses a stationary phase consisting of an organic moiety 
chemically bonded to the surface of silica through the surface silanol groups. Since 
the organic moieties are generally long-chain hydrocarbons, the mobile phases are 
generally polar. In this mode, the more polar solutes are eluted first while the non-
polar compounds are eluted later. The silanol group can react with a chlorosilane 
group to form the popular (ODS & C18) octadecylsilane packing. 
E.g. Octadecylsilane (ODS or C18).  
 
    CH3                  CH3    
                   
 Si     OH + Cl – Si – (CH2)17 – CH3                  Si – O – Si – (CH2)17 – CH3 + HCl 
              
    CH3                         CH3   
 
For silica based bonded materials, the suitable working pH range is 2 - 8. At 
pH values of less than 2, the Si-C bond is attached, and at the higher pH values, 
hydrolysis of the siloxane takes place which leads to degradation or destruction of the 
packing. In most of the applications of RP-HPLC, elution is carried out with highly 
polar solvents such as methanol, acetonitrile or tetrahydrofuran in various 
concentrations. [9a] 
 
Reverse phase mobile phase 
The primary constituent of RP-HPLC mobile phase is water. Water miscible 
solvents such as methanol, ethanol, acetonitrile, dioxane, tetrahydrofuran and 
dimethyl formamide are added to adjust the polarity of the mobile phase. Additionally 
acids, bases, buffers and/or ionic surfactants are added. The water should be of high 
quality, either distilled or demineralised water. 
 
The most widely used organic modifiers are methanol, acetonitrile and 
tetrahydrofuran. Methanol and acetonitrile have comparable polarities but acetonitrile 
is an aprotic solvent. Ethanol, 1-propanol and 2-propanol are also useful but less polar 
than methanol. Dioxane, tetrahydrofuran are aprotic solvents that are less polar than 
acetonitrile. Reverse phase mobile phases are generally non-flammable due to high 
water content. Degassing is quite important with reverse phase mobile phases. [9b] 
 
Detectors in HPLC 
 
Characteristics of ideal detectors 
1. Adequate sensitivity. 
2. Good stability and reproducibility. 
3. A linear response to analyte. 
4. A short response time that is independent of flow rate. 
5. High reliability. 
6. Minimal internal volume in order to zone broadening. [9c] 
 
Liquid chromatographic detectors are of two basic types, 
1. Differential or bulk property detector 
2. Selective or solute property detector 
 
Differential or bulk property detector 
Differential or bulk property detector provides a differential measurement of a 
bulk property that is possessed by both the analyte and the mobile phase. 
e.g., Refractive index, dielectric constant. 
 
Selective or solute property detector 
Measure the property of an analyte which is not possessed by the mobile 
phase. 
e.g., UV absorbance, fluorescence. 
 
 
 
 
 
 
1.3   RELATED SUBSTANCES AND IMPURITIES 
 
Preface 
The pharmaceutical industry is required by the Food, Drug and Cosmetic Act 
to establish the identity and purity of all marketed drug products. The United States 
Food and Drug Administration (FDA) and other regulatory bodies around the world 
insist on the requirement of impurities in drug substance and drug product when 
present at threshold level recommended by the International Conference on 
Harmonisation (ICH) should be isolated and characterized. [10]  
 
The identification of process related impurities and degradation products can 
provide an understanding on production of impurities and define degradation 
mechanism.  
 
Definitions 
 Impurity: “any entity of the drug substances (bulk material) or drug (final 
container product) that is not the chemical entity defined as the drug substance, an 
excipient, or other additives to the drug product”. 
 
 Degradation product: The compound produced as a result of decomposition of 
the material of interest or Active Pharmaceutical Ingredient are often called 
degradation products (degradants). Degradation could occur as a result of changes 
during processing or storage (e.g., oxidation, aggregation and proteolysis). 
 
In the pharmaceutical world, an impurity is generally considered as any other 
organic material besides the drug substance or Active Pharmaceutical Ingredient, that 
arises out of synthesis. Most of the time, the inorganic contaminants are not given 
adequate consideration as impurities unless they are toxic, such as heavy metals or 
arsenic. 
 
Organic Volatile Impurities (OVI) which are usually residual solvents as well 
as other organic volatile impurities used in the synthesis are often considered virtual 
impurities. 
 
Interaction products are produced during formulation processes and 
degradation products. 
 
Therefore, for all intents and purposes, various contaminants mentioned here 
can be called impurities and should be labelled as such because they decrease the 
purity of API. 
 
Isolation and characterization of impurities 
Impurities are generally assumed to be inferior to API because they might not 
have the same level of pharmacological activity. However, they are not necessarily 
always inferior. From the standpoint of its usage, the drug substance is not 
compromised in terms of purity even if it contains another material with superior 
pharmacological or toxicological properties. Therefore, any extraneous material 
present in the drug substances or active ingredients must be considered as an impurity 
even if it is totally inert or has superior pharmacologic properties so that an 
appropriate evaluation of its content in the drug product can be made.  
 
In many final pharmaceutical products, test for related substances is performed 
as a part of the chemical quality control. This test is intended to check that the content 
of impurities structurally related to the active pharmaceutical ingredients (related 
substances), are at a very low level. This is important, as related substances can affect 
the efficacy of the final pharmaceutical product especially, degradation products from 
the API.  
 
Identification and determination 
The first step of impurity profiling is the detection of the impurities. High 
resolution NMR and mass spectrometry can play an important role in getting a finger 
print on the purity of the sample. 
 
Impurity profiling in synthetic drug research 
 The use of analytical method is of utmost importance in all phases of synthetic 
research and other related areas (biotechnology, extraction of materials of plant and 
animal origin) aimed to introduce new chemical entities in therapy. 
During the course of drug development, the qualititative impurity profile may 
change as a result of, for example, changes in synthetic route, drug product 
formulation, storage conditions and container / closure system. These changes result 
in increased levels of previously observed impurities above the identification and/or 
qualification threshold limits or new impurities not previously identified or qualified. 
When these impurities are above the threshold limits, consideration for identification 
and qualification of the level of the impurity is indicated and one of the decision trees 
for safety studies should be consulted. Safety studies should compare the new drug 
substance containing new a representative level of the impurity with previously 
qualified materials. Although studies using the isolated impurity are also acceptable, 
validated method for the separation and quantification of different impurities are 
preferred. 
 
Various terms of impurities 
  By product 
 Degradation product 
 Interaction product 
 Intermediate 
 Related product 
 Transformation product 
 Toxic impurities 
 Organic volatile impurities 
 Foreign substances 
 Enantiomeric impurities 
 
ICH Terminology 
 According to ICH guidelines, impurities are classified into the following three 
categories for the drug substance produced by chemical synthesis.  
 
1. Organic impurities (starting materials, process related products, intermediates 
and degradation products). 
2. Inorganic impurities (salts, catalyst, ligands and heavy metals or other residual 
metals). 
3. Residual solvents (organic and inorganic liquids used during production 
and/or recrystallization). 
 
Table No: 3 ICH Quality Guidelines 
 Q1 A -  Stability testing of new drug substances and products 
 Q2 A -  Validation of analytical procedures 
 Q3 A -  Impurities in drug substances 
 Q3 B -  Impurities in new drug products 
 Q6 A - Specifications: Test procedures and acceptance criteria for 
      new drug substances and new drug products 
 
Any impurity that may be present in the starting material has the potential to 
be carried into the active ingredient of interest. 
 
The most obvious source of impurities is the synthesis, where intermediates 
and by-products may be carried into the API as impurities or an intermediate and 
become a source of other impurities resulting from them. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4 VALIDATION 
 
The word “Validation” means “Assessment” of validity or “action of proving 
effectiveness”. [11] 
 
System Suitability 
System suitability testing is an integral part of many analytical procedures. 
The tests are based on the concept that the equipment, electronics, analytical 
operations and samples to be analyzed constitute an integral system that can be 
evaluated as such. 
 
The system suitability testing parameters established for the liquid 
chromatographic procedure are: 
¾ Retention time  
¾ Symmetry factor or tailing factor 
¾ Theoretical plates 
¾ Resolution 
 
General considerations 
 
Retention Time (t) 
This is the time of emergence of the peak maximum of a component after 
injection. 
 
Symmetry factor (or) Tailing factor (T) 
T = W / 2f 
 
The assessment of peak shape is in terms of symmetry factor. 
W  -    Width of peak at 5 % height 
 f    -   Distance from the peak maximum to the leading edge of the peak, 
the distance being measured at a point 5 % of the peak height from 
the baseline (or) width of front half of the peak at 5 % height 
 
Number of theoretical plates (N) 
N = 5.54 T / W 
The assessment of performance of efficiency of a column is in terms of the 
number of theoretical plates. 
W - Width of peak at half height 
 
Resolution (R)  
  
R = 2 (t2 – t1) / W2 + W1 
 
This gives the resolution between the measured peaks on the chromatogram 
Where, 
t2 and t1 -     Retention times of the two components. 
W2 and W1   -   Widths of the components at the bases of the peaks obtained by         
 extrapolating the relatively straight sides of  the peaks to the    
 baseline.[12] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  2. DRUG PROFILE 
 
Name 
 Nevirapine 
 
IUPAC Name 
 11-Cyclopropy1-5, 11-dihydro-4-methy1-6H-dipyrido [3, 2-b : 20, 30-e] [1, 4] 
diazepin-6-one. [13] 
 
Structure of Nevirapine 
NN
CH3
N
H
N
O
 
 
Molecular Formula  : C15H14N4O 
 
Molecular Weight  : 266.30 
 
CAS Number   : 129618-40-2 
 
Category   : Non-nucleoside reverse transcriptase inhibitor  
      (NNRTI), class of anti-retroviral. 
 
Description   : White or almost white, odorless to nearly odorless, 
                crystalline powder. 
 
Solubility   : Practically insoluble in water, slightly soluble in  
      alcohol and in methanol. 
 
Storage   : Store at 25 °C (77 °F), excursions permitted to  
      15 °C-30 °C (59 °F-86 °F).  
 
 
 
 
History: 
 Nevirapine was discovered by Hargrave et al. at Boehringer Ingelheim 
Pharmaceuticals, Inc., one of the Boehringer Ingelheim group of companies. It is 
covered by U.S. Patent 5,366,972 and corresponding foreign patents. Nevirapine was 
the first NNRTI approved by the U.S. Food and Drug Administration (FDA). It was 
approved June 21, 1996 for adults and september 11, 1998 for children. [14] At present 
nevirapine is an official drug in Indian Pharmacopoeia [15], British 
Pharmacopoeia [16] and United States Pharmacopoeia.[17] 
 
Impurities   : Specified impurities A, B and C. [16] 
 
NN
CH3
N
H
N
O
R  
 
Related Substance A. R = C2H5 : 11-ethyl-4-methyl-5, 11-dihydro-6H-dipyrido          
[3, 2-b: 2’,3’-e] [1,4] diazepin-6-one. 
 
Related Substance B. R = H : 4-methyl-5, 11-dihydro-6H-dipyrido                         
[3, 2- b: 2’,3’-e]  [1, 4] diazepin-6-one. 
 
Impurity C. R = CH2-CH2-CH3 : 4-methyl-11-propyl-5, 11-dihydro-6H-dipyrido       
[3, 2-b : 2’, 3’-e] [1,4] diazepin-6-one. 
 
Dosage and administration: 200 mg tablets - Oral route of administration 
 
Half life : 25 - 30 hours  
 
Brand Names : Nevimune 200 mg, Nevivir 200 mg 
 
 
Mode of action 
 Nevirapine diffuses into the cell and binds to reverse transcriptase adjacent to 
the catalytic site. This induces conformational changes that inactivate the enzyme. 
Resistance develops rapidly in cells exposed to nevirapine. High-level resistance is 
associated with mutations at reverse transcriptase codons 101, 103, 106, 108, 135, 
181, 188 and 190. 
 
Pharmacokinetics: 
  
Absorption 
 Nevirapine is well absorbed orally. It is readily crosses the placenta and has 
been found in breast milk, a feature that has encouraged use of nevirapine  for 
pprevention of mother-to-child transmission of HIV. 90 % (Absolute bioavailability 
93 ± 9 %), CSF to plasma level is 45 %. [18] 
 
Distribution 
  Nevirapine is highly lipophilic and is essentially non-ionized at               
physiological pH.  
 
Metabolism 
  Oxidative metabolism of nevirapine in the liver by cytochrome P450 isoforms 
CYP3A4 and CYP2B6 produces several metabolites including 2 -, 3 -, 8 - and          
12 -  hydroxynevirapine. 
 
Elimination 
 Cytochrome P450 metabolism, glucuronide conjugation and urinary excretion 
of glucuronidated metabolites represent the primary route of nevirapine 
biotransformation and elimination. 
 
Drug Interactions:  
 Rifamibicin and ketoconazole are contraindicated in patients receiving 
nevirapine. Plasma ethinyl estradiol level decreases significantly with nevirapine 
coadministration. Although it can lower plasma concentrations of protease   
inhibitors. [19] 
 
 
3. LITERATURE REVIEW 
 
1. Anand Babu K, et al., (2011) [20] have developed and validated method for 
the simultaneous estimation of zidovudine, lamivudine and nevirapine tablets 
by RP-HPLC. 
Column  : Hypersil BDS C18 column 
Mobile Phase  : Ammonium acetate buffer : acetonitrile  [75 : 25] 
Flow Rate  : 1 mL/min 
Detector  : UV detector set at 270 nm 
 
2. D'Avolio A, et al., (2011) [21] have validated a sensitive and accurate high 
performance liquid chromatography-mass spectrometric (HPLC-MS) method 
for the intracellular determination of 14 anti-retroviral drugs in peripheral 
blood mononuclear cells (PBMCs) for HIV patients. 
 Column  : Atlantis T3 column 
 Mobile Phase  : Gradient elution water (0.05% formic acid) and ACN 
 Flow Rate  : 1 mL/min 
 Detector  : UV detection at 284 nm 
 
3. Rohini, et al., (2011) [22] have estimated a reverse phase high performance 
liquid chromatography method for nevirapine in tablets. 
Column  : Symmetry C18 column 
Mobile Phase  : Acetonitrile : phosphate buffer [65 : 35] 
Flow Rate  : 0.8 mL/min 
Detector  : UV detection at 283 nm 
 
4. Shewiyo D H, et al., ( 2011) [23] have developed and validated an improved 
method for the simultaneous analysis of lamivudine, stavudine and nevirapine 
using high performance thin layer chromatography (HPTLC). 
 Column  : C18 Column 
 Mobile Phase  : Ethyl acetate : methanol : toluene  : ammonia  
      [38.7 : 19.4 : 38.7 : 3.2] 
 Detector  : Densitometric detection 
5. D'Avolio A, et al., (2010) [24] have developed a bioanalytical method for the 
determination of most commonly prescribed protease inhibitors (saquinavir, 
atazanavir, amprenavir, darunavir, lopinavir and ritonavir) and non-nucleoside 
reverse transcriptase inhibitors (etravirine, efavirenz and nevirapine). C18 
column was used to analyse the samples. 
 
6. Else L, et al., (2010) [25] described a simple, fast and sensitive HPLC-MS/MS 
method for determination of the commonly used protease inhibitors (PI) 
amprenavir, atazanavir, darunavir, lopinavir, ritonavir, saquinavir and the non-
nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine. 
 Column  : C18 column  
 Mobile Phase  : Gradient acetonitrile and 0.05% formic acid 
Detector  : UV detection at 280 nm 
 
7. Hemanth Kumar A K, et al., (2010) [26] have described a relatively simple 
and accurate method to estimate anti-retroviral drugs in pharmaceutical 
preparation is by spectrophotometric method. 
 Column  : C18 column 
 Detector  : UV detection at 300, 285 and 270 nm 
 
8. Kaale E, et al., (2010) [27] have developed an inter-laboratory investigation on 
the use of high performance thin layer chromatography to perform assays of 
lamivudine, zidovudine, metronidazole, nevirapine, and quinine composite 
samples. 
  
9. Li Z, et al., (2010) [28] have developed a new high throughput LC-MS/MS 
method for the simultaneous determination of lamivudine, stavudine  
and nevirapine in human plasma with zidovudine as an internal standard. 
Shiseido C8 column was used. 
 
10. Ren C, et al., (2010) [29] have developed a highly sensitive and specific      
LC-MS/MS assay method and validated to quantify nevirapine and its         
five metabolites [2-, 3-, 8-, 12-hydroxyl NVP and 4-carboxyl NVP] 
simultaneously in baboon serum. 
11. Vogel M, et al., (2010) [30] have described a simple, stable and specific gas 
chromatography-mass spectrometry method for the determination 
of nevirapine in plasma. 
 
12. Elens L, et al., (2009) [31] have reported an ultra performance liquid 
chromatography (UPLC) diode array detection method for the simultaneous 
quantification of the HIV protease inhibitors amprenavir, atazanavir, indinavir, 
lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir and the non-nucleoside 
reverse transcriptase inhibitors efavirenz and nevirapine. C8 column was used 
to analyse the sample. 
 
13. Malm M, et al., (2009) [32] have developed and validated a bioanalytical 
method for the determination of lamivudine, zidovudine and nevirapine in 100 
µL capillary blood applied onto sampling paper. 
 Column  : Zorbax SB C8 column 
 Mobile Phase  : 2 step gradient:  methanol : sodium acetate buffer  
                 [pH 3.95, 15 : 85] and  [pH 3.95, 50 : 50] 
 Flow Rate  : 1.0 mL/min 
 Detector  : UV detection at 265 nm 
. 
14. Martin J, et al., (2009) [33] have described a liquid chromatography-tandem 
mass spectrometry assay for simultaneous determination of the plasma 
concentration of 11 anti-retroviral agents (nevirapine, indinavir, atazanavir, 
amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir 
and maraviroc). 
 
15. Mandloi D K, et al., (2009) [34]  have developed a simple, highly sensitive, 
isocratic reverse phase high performance liquid chromatography method for 
the determination of nevirapine in the bulk drug and tablet dosage forms. 
Column  : Luna 5 μ, C18 column  
Mobile Phase  : Methanol and water [89 : 11] 
Flow Rate  : 1 mL/min 
Detector  : UV detection at 284 nm 
16. Nageswara Rao R, et al., (2009) [35] have developed and reported a  simple, 
rapid, reliable and highly sensitive online two-dimensional reverse phase 
liquid chromatography-tandem mass spectrometric method to determine    
anti-retroviral drugs viz., abacavir, nevirapine and indinavir in rat serum and 
urine. 
 Column  : C18 column 
 Detector  : ESI-MS/MS detection  
 
17. Prasada Rao C H, et al., (2009)  [36] have developed a reverse phase high 
performance liquid chromatography method for the estimation of nevirapine in 
bulk drug and pharmaceutical dosage forms. 
Column  : Octa decyl silane column 
Mobile Phase  : Methanol and acetate buffer [60 : 40] 
Flow Rate  : 1.0 mL/min 
Detector  : UV detection at 280 nm 
 
18. Purnima D. Hamrapurkar, et al., (2009) [37] have reported a validated 
method for the estimation of nevirapine from bulk drug and tablet formulations 
using appropriate solvent system on TLC plates.  
HPTLC plates  : Precoated silica gel, GF254, 10 cm x 20 cm  
Solvent  : Ethyl acetate : glacial acetic acid (10 : 0.1) 
Detection  : Densitometrically scanned at 283 nm 
 
19. Stieger N, et al., (2009) [38] have developed UV spectrophotometric method 
for the quantitative determination of nevirapine in water, methanol and         
0.1 N HCl. 
 
20. D'Avolio A, et al., (2008) [39] have developed and validated a new method 
using high-performance liquid chromatography coupled with PDA detector for 
the quantification of plasma concentrations of 11 anti-retroviral agents 
including nevirapine and its metabolites. 
 
21. Heine R, et al., (2008) [40] have developed a bioanalytical method for the 
determination of most commonly prescribed protease inhibitors (atazanavir, 
darunavir, lopinavir and ritonavir) and non-nucleoside reverse transcriptase 
inhibitors (efavirenz and nevirapine). 
 Column  : C18 column (150 mm x 2.0 mm) 
 Mobile Phase  : Acetonitrile, methanol and ZnSO4 in water [1 : 1 : 2] 
 
22. Notari S, et al., (2008) [41] have quantified abacavir, amprenavir, didanosine, 
efavirenz, nevirapine and stavudine in the plasma of HIV infected patients, by 
standard addition analysis.   
 
23. Palaniappan Mohanraj, et al., (2008) [42] have described the method for 
determination of nevirapine in tablet dosage forms by simple and rapid       
RP-HPLC method. 
 Column  : ODS column 
 Mobile Phase  : Methanol and water [89 : 11] 
 Flow Rate  : 1 mL/min 
 Detector  : UV detection at 284 nm 
 
24. Gehrig A K, et al., (2007) [43] have developed a bioanalytical method for 
determination of some of the anti-HIV drugs including nevirapine. 
 Column  : Nucleosil C18 column 
 Mobile Phase  : Gradient 20 mM ammonium acetate including 0.1 % 
       aqueous acetic acid and acetonitrile 
 Detector  :  Electrospray ionisation / tandem mass spectrometry 
 
25. Herve Rebiere, et al., (2007) [44] have developed and validated two methods 
by reverse phase liquid chromatography for the analysis of 19 anti-retroviral 
molecules. 
Method I: (NRTI) 
Column  : YMC pack ODS 
Mobile Phase  : Gradient ammonium acetate buffer pH 4.0 : methanol 
Flow Rate  : 1 mL/min 
Detector  : UV detection at 270 nm 
Method II: (NNRTI & PI) 
Column  : Symmetry C18 
Mobile Phase  : Gradient potassium phosphate buffer pH 5.6 : ACN 
Flow Rate  : 1.5 mL/min 
Detector  : UV detection at 260 nm 
 
26. Liu Z, et al., (2007) [45] have reported a rapid highly sensitive and specific 
electrospray ionization liquid chromatography/tandem mass spectrometry  
method for quantification of nevirapine and its two metabolites, 2-
hydroxynevirapine and nevirapine 4-carboxylic acid. 
 
27. Mistri H N, et al., (2007) [46] have developed and validated a selective and 
high throughput liquid chromatography-tandem mass spectrometry method to 
detect and simultaneously quantify lamivudine, stavudine and nevirapine in 
human plasma using metaxalone as internal standard. 
 Column  : Symmetry C18 
 Mobile Phase  : Water : acetonitrile [20 : 80] 
 
28. Rowland L S, et al., (2007) [47] have developed and validated a multiple  
reaction monitoring LC/MS/MS method for the analysis of nevirapine 
oxidative metabolites, 2-hydroxynevirapine, 2-hydroxynevirapine, 3-hydroxy 
nevirapine, 8-hydroxynevirapine, 12-hydroxynevirapine and 4-carboxy 
nevirapine in human plasma. 
 
29. Weller D R, et al., (2007) [48] have described an efficient, isocratic high 
performance liquid chromatography method for determining human 
immunodeficiency virus non-nucleoside reverse transcriptase inhibitors and 
protease inhibitors in plasma is advantageous for laboratories participating in 
clinical trials and therapeutic drug monitoring programs, or conducting small 
animal research. 
 Column  : S3 column  
 Detector  : Detection at 212 nm 
 
30. Geetha Ramachandran, et al., (2006) [49] have described a reverse phase high 
performance liquid chromatographic method for simultaneous determination 
of plasma zidovudine and nevirapine. 
Column  : C18  column  
Mobile Phase  : Potassium dihydrogen phosphate pH 7.5 : acetonitrile  
     [75 : 25]  
Flow Rate  : 1.5 mL/min 
Detector  : UV detection at 260 nm 
 
31. Notari S, et al., (2006) [50] have developed a HPLC-UV method to quantify 
simultaneously some HIV protease inhibitors, reverse transcriptase inhibitors 
and non-nucleoside reverse transcriptase inhibitors including nevirapine in 
human plasma. 
 Column  : C18 Symmetry 
 Mobile Phase  : Linear gradient 0.01 M potassium dihydrogen  
      phosphate and acetonitrile 
 Flow Rate  : 1.0 mL/min 
 Detector  : UV detection at 240 and 260 nm 
 
32. Namita Kapoor, et al., (2006) [51] have developed a method for the 
simultaneous determination of lamivudine, stavudine and nevirapine in anti-
retroviral fixed dose combinations by high performance liquid 
chromatography. 
 Column  : Symmetry C18 column 
 Mobile Phase  : Gradient elution  
      Sol. A: Acetate buffer pH 3.5: methanol [80 : 20]  
      Sol. B: Acetonitrile : isopropyl alcohol [50 : 50]  
Flow Rate  : 0.6 mL/min 
Detector  : UV detection at 270 nm 
 
33. Ramachandran G, et al., (2006) [52] have described a simple, fast, isocratic, 
reverse phase high performance liquid chromatographic method for 
simultaneous determination of plasma zidovudine and nevirapine. 
 Column  : C18 column 
 Mobile Phase  : Potassium dihydrogen phosphate pH 7.5 and  
        acetonitrile [72 : 28]. 
 Detector  : UV detection at 260 nm 
 
34. Rezk N L, et al., (2006) [53] have reported full validation of an analytical 
method that combines atazanavir with HIV protease inhibitors and               
non-nucleoside reverse transcriptase inhibitors including nevirapine. 
 Column  : Zorbax C18 
 Detector  : Detection at 210 nm 
 
35. Sarkar M, et al., (2006) [54] have developed and validated HPLC and an UV 
spectrophotometric method for the quantitative determination of three 
antiretroviral drugs viz., lamivudine, stavudine and nevirapine that constitute 
one of the first line regimens in antiretroviral therapy. 
 Column  : C18 symmetry  
 Detector  : UV detection at 270, 265 and 313 nm 
 
36. Silverthorn C F, et al., (2006) [55] have validated clinically relevant assay for 
the assessment of nevirapine concentrations in neonate plasma samples. 
 Column  : C8 column 
 Detector  : UV detection at 280 nm 
 
37. Anbazhagan S, et al., (2005) [56] have described the simultaneous 
quantification of stavudine, lamivudine and nevirapine in tablets by UV 
spectroscopy, reverse phase HPLC and HPTLC methods. 
 Column  : C18 ODS-Hypersil column 
 Mobile Phase  : Sodium phosphate buffer : acetonitrile [4 : 1] 
 Detector  : UV detection at 266, 271 and 315 nm 
 
38. Colombo S, et al., (2005) [57] have described a sensitive and accurate liquid 
chromatography-tandem mass spectrometric method for the intracellular 
determination of nine antiretroviral drugs in human peripheral blood 
mononuclear cells (PBMCs). PBMCs are isolated by density gradient 
centrifugation using vacutainer CPT tubes and cell count is performed with a 
coulter instrument. 
 Column  : RP C18 symmetry shield 
 Mobile Phase  : Gradient elution ammonium acetate and acetonitrile 
 Detector  : UV detection  
 39. Koal T, et al., (2005) [58] were quantified for the anti-retroviral drugs, i.e., PI 
and NNRTI in dried blood spots from HIV/AIDS patient whole blood samples 
as the basis for therapeutic drug monitoring by a robust simultaneous liquid 
chromatography/tandem mass spectrometry method. This study includes PI 
and NNRTI using phenomenex synergy max column. 
 
40. Lemmer P, et al., (2005) [59] have developed an accurate, selective, and 
sensitive method for the determination of the non-nucleoside reverse 
transcriptase inhibitors nevirapine and efavirenz in human plasma using gas 
chromatography-mass spectroscopy. 
 
41. Schuman M, et al., (2005) [60] have developed and validated a  RP-HPLC 
method using photo diode array detection for the simultaneous quantification 
of lamivudine, stavudine, nevirapine, zidovudine, methylparaben and 
propylparaben in solid and liquid drug formulations. 
 Column  : Symmetry C8 column 
 Mobile Phase  : Gradient 50 mM NaH2PO4 pH 3.8 and ACN  
 Flow Rate  : Gradient (0.5 to 1.0 mL/min) 
 Detector  : UV detection  
 
42. Tribut O, et al., (2005) [61] have reported simultaneous quantification of     
anti-retroviral drugs and it metabolites in human plasma. 
 Column  : X-TERRA column 
 Mobile Phase  : Gradient water (3 mM pyrrolidine) and  acetonitrile 
 Detector  : UV detection  
 
 
43. Dailly E, et al., (2004) [62] have proposed a global method for therapeutic drug 
monitoring of atazanavir, a novel protease inhibitor along with all other 
protease inhibitors and non-nucleoside reverse transcriptase inhibitors which 
are currently used to treat HIV patients. All drugs are extracted after a liquid-
liquid extraction and separated on a C18 column with a binary gradient elution 
except lopinavir. The absorbance is measured at 259 nm except for lopinavir 
(205 nm) and nevirapine (320 nm). 
 
44. Dubuisson J G, et al., (2004) [63] described a fast, inexpensive thin-layer 
chromatography method to detect the presence of NVP in human plasma. 
Clinical samples with nevirapine concentrations predetermined by high 
performance liquid chromatography were used to validate the TLC method. 
 
45. Egge Jacobsen W, et al., (2004) [64] have reported an analytical assay based 
on automated sample preparation and liquid chromatography coupled with 
electrospray mass spectrometry for the quantification of some of the anti-viral 
drugs. 
 
46. Kaul N, et al., (2004) [65] have developed and validated sensitive, selective, 
precise and stability indicating  HPTLC method of analysis of nevirapine both 
as a bulk drug and in formulations. 
 Mobile Phase   : Toluene : carbon tetrachloride: methanol: acetone :
         ammonia [3.5 : 3.5 : 2.0 : 1.0 : 0.05] 
Detection   :   Densitometric analysis, absorbance mode at 289 nm 
 
47. Rezk N L, et al., (2004) [66] have described an accurate, sensitive, and specific 
reverse phase high performance liquid chromatography assay for the 
simultaneous quantitative determination of HIV protease inhibitors and non-
nucleoside reverse transcriptase inhibitors in human blood plasma.  
 Mobile Phase  : Linear gradient phosphate buffer (pH 4.5), acetonitrile, 
      methanol and TFA. 
 Flow Rate  : Gradient mobile phase flow rate (0.9 - 1.1 mL) 
 Detector  : UV detection  
48. Bregt S Kappelhoff, et al., (2003) [67] have developed method for the 
simultaneous determination of the NNRTI efavirenz and nevirapine in human 
plasma using liquid chromatography. 
Column  : Zorbax C18 column 
Mobile Phase  : Ammonium acetate : methanol       
Flow Rate  : 1 mL/min 
Detector  : UV detection at 275 nm 
 
49. Chi J, et al., (2003) [68] have developed a sensitive and rapid liquid 
chromatography tandem mass spectrometry method to measure the levels of 
the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine in human 
plasma. LC-MS-MS in positive mode used pairs of ions at m/z of 267/226 for 
nevirapine and 628/421 for the IS respectively. 
 
50. Droste J A, et al., (2003) [69] have described a reversed phase high 
performance liquid chromatography method for the simultaneous quantitative 
determination of the HIV protease inhibitors and the non-nucleoside reverse 
transcriptase inhibitor nevirapine in human plasma. 
 Column  : OmniSpher C18 column  
 Detector  : UV detection at 215 nm and 280 nm 
 
51. Jingduan Chi, et al., (2003) [70] have developed a sensitive method to measure 
the levels of the NNRTI nevirapine in human plasma by liquid 
chromatography tandem mass spectrometry. 
 Column  : Zorbax XDB C8 reverse phase column 
 Mobile Phase  : Buffer pH 4.1 and acetonitrile [gradient flow]  
 Flow Rate  : 400 µL/min 
 Mass analyser : Triple quadrupole mass spectrometer 
 
52. Kappelhoff B S, et al., (2003) [71] have described a simple and rapid high 
performance liquid chromatographic method for the simultaneous 
quantification of efavirenz and nevirapine in human plasma suitable for 
therapeutic drug monitoring. The drugs were separated from endogenous 
compounds by isocratic reverse phase high performance liquid 
chromatography with ultraviolet detection at 275 nm. 
 
53. Rezk N L, et al., (2003) [72] have reported an accurate, sensitive and specific 
reverse phase high performance liquid chromatography assay for the 
simultaneous quantitative determination of the nucleoside reverse transcriptase 
inhibitors, non-nucleoside reverse transcriptase inhibitor nevirapine in human 
blood plasma. The new polarity dC C18 silica column used in this method 
provides better resolution and peak shape and detected using four different 
ultraviolet wavelengths for accurate and specific quantitation of the analytes. 
 
54. Rentsch K M, (2003) [73] has developed a sensitive and rapid liquid 
chromatography tandem mass spectrometry method to measure the levels of 
the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine in human 
plasma. LC-MS-MS in positive mode used pairs of ions at m/z of 267/226 for 
NVP and 628/421 for the IS, respectively. 
 
55. A. Volosov, et al., (2002) [74] have developed simple rapid method for 
quantification of antiretrovirals by liquid chromatography tandem mass 
spectrometry. 
Column  : Supelco LC18 DB chromatographic column 
Mobile Phase  : Ammonium acetate : methanol      
Flow Rate  : 1 mL/min 
Detector  : UV detection at 260 nm 
 
56. Fan B, et al., (2002) [75] have developed a new high-performance liquid 
chromatography assay for the simultaneous determination of 
zidovudine/lamivudine/nevirapine in human plasma. 
 Column  : Octylsilane column 
 Mobile Phase  : Sodium phosphate buffer : acetonitrile [86:14]  
 Detector  : UV detection at 265 nm 
 
57. Laurito T L, et al., (2002) [76] have developed and validated a rapid, sensitive 
and specific method to quantify nevirapine in human plasma using 
dibenzepine as the internal standard. C18 analytical column was used with UV 
detection of 268 nm. This method was employed in a bioequivalence study of 
two nevirapine tablet formulations. 
 
58. Langmann P, et al., (2002) [77] have developed a sensitive and rapid gas 
chromatographic method to determine the levels of the HIV-1 non-nucleoside 
reverse transcriptase inhibitor nevirapine in human plasma. CP-Sil 5CB 
capillary column with a nitrogen phosphorous detector, Helium 5.0 was used 
as carrier gas. 
 
59. Marchei E, et al., (2002) [78] have developed a simple method for the 
simultaneous determination of zidovudine and nevirapine in human plasma by 
reverse phase liquid chromatography. 
 Column  : Zorbax SB C18 column 
 Mobile Phase  : Potassium dihydrogen phosphate pH 6.5 : acetonitrile 
       [83 : 17] 
 Detector  : UV detection at 265 nm  
 
60. Marzolini C, et al., (2002) [79] have adapted the HPLC method previously 
described for the simultaneous assay of amprenavir, ritonavir, indinavir, 
saquinavir, nelfinavir and efavirenz after solid-phase extraction is proposed 
here for the separate analysis of the newer PI lopinavir and the 
NNRTI nevirapine. 
 Column  : Nucleosil C18 AB 
 Mobile Phase  : Gradient elution acetonitrile: phosphate buffer pH 5.07 
 Detector  : UV detection at 201 and 282 nm 
 
61. Naser L Rezk, et al., (2002) [80] have described a reverse phase high 
performance liquid chromatography assay for the simultaneous quantitative 
determination of three HIV NNRTI nevirapine, delavirdine, and efavirenz in 
human blood plasma. 
Column  : Eclipse XDB C8 column  
Mobile Phase  : Sodium phosphate buffer (pH 4.8) and    
    acetonitrile [Gradient flow] 
Flow Rate  : 1.5 mL/min 
Detector  : UV detection at 224 nm 
 
62. Poirier J M, et al., (2002) [81] have developed a sensitive and selective liquid 
chromatographic assay for the determination of six protease inhibitors active 
metabolite of nelfinavir and the non-nucleoside reverse transcriptase inhibitor 
efavirenz. Narrow bore C18 reverse phase column was used with gradient 
elution. Double ultraviolet detection at 265 nm (amprenavir) and at 210 nm 
(for all other assayed drugs and internal standard) was used. 
 
63. Rezk N L, et al., (2002) [82] have described a simple reverse phase high 
performance liquid chromatography assay for the simultaneous quantitative 
determination of three HIV non-nucleoside reverse transcriptase inhibitors 
(nevirapine, delavirdine and efavirenz) in human blood plasma. Symmetry C18 
column has been used with UV detection at 270 nm 
 
64. Titier K, et al., (2002) [83] have developed a selective and sensitive high 
performance liquid chromatographic method for the determination of the 
human immunodeficiency virus protease inhibitors and the non-nucleoside 
reverse transcriptase inhibitors (nevirapine and efavirenz). 
 Column  : Stability RP C18 column 
 Mobile Phase  : Gradient of acetonitrile and phosphate buffer pH 5.65 
 Detector  : UV detection at 240 nm 
 
65. Tribut O, et al., (2002) [84] have described a rapid (less than 30 min), 
sensitive, and specific liquid chromatography method for simultaneous assay 
of nine anti-retroviral drugs in human plasma. This technique allowed 
therapeutic drug monitoring of six approved protease inhibitors (amprenavir, 
indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) and two approved 
non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine). 
 
 Column  : X-TERRA column 
 Mobile Phase  : Water and acetonitrile 
 Detector  : Detection with a diode array detector 
 
66. Dailly E, et al., (2001) [85] have reported a single HPLC assay for therapeutic 
drug monitoring of 5 HIV protease inhibitors (indinavir, amprenavir, 
saquinavir, ritonavir and nelfinavir) and a non-nucleoside reverse transcriptase 
inhibitor (nevirapine) in human plasma. 
 Column  : Symmetry C18 column 
 Mobile Phase  : Gradient elution of solvent A acetonitrile and 0.025 M 
       tetramethyl ammonium perchlorate [55:45] and  
       solvent B methanol 
 Detector  : UV detection at 320 nm, 259 nm, 254 nm and 239 nm 
 
67. Lopez R M, et al., (2001) [86] have described a fast, simple isocratic reverse 
phase high performance liquid chromatography method with a 30 mm long 
column for assaying nevirapine in human serum. 
Column  : C18 column 
Mobile Phase  : Phosphate buffer (pH 5) : acetonitrile [82:18] 
 Flow Rate  : 1.0 mL/min. 
Detector  : UV detection was performed at 240 nm 
 
68. Villani P, et al., (2001) [87] have developed an analytical technique using 
liquid chromatography (LC) coupled with electrospray mass spectrometry  for 
the simultaneous determination of five protease inhibitors : saquinavir, 
indinavir, ritonavir, nelfinavir and amprenavir; and three non-nucleoside 
reverse transcriptase inhibitors : nevirapine, delavirdine and efavirenz, in 
human plasma. 
 Column  : C18 reverse phase  
 Mobile Phase  : Linear gradient with water and acetonitrile 
 Detector  : Mass spectrometry detection 
 
69. Aymard G, et al., (2000) [88] have described a new high performance liquid 
chromatography with UV detection assay for the simultaneous determination 
of protease inhibitors, nucleoside and non-nucleoside reverse transcriptase 
inhibitors using a plasma samples. 
 Column  : C18 symmetry column 
 Mobile Phase  : Sodium phosphate buffer : acetonitrile [50:50]  
 Detector  : UV detection at 241, 254 and 261 nm 
 
70. Hollanders R M, et al., (2000) [89] have reported  a sensitive and rapid high 
performance liquid chromatography method to measure the levels of the 
nevirapine in human plasma.  
Column  : Hypersil ODS column  
Mobile Phase  : Acetonitrile and phosphate buffer pH 4.5 [30 : 70] 
Flow Rate : 1.0 mL/min  
Detector  : UV detection at 280 nm 
 
71. Pav J W, et al., (1999) [90] have optimized and validated a reverse phase 
HPLC method for the determination of nevirapine in human plasma, serum, 
milk and cerebrospinal fluid. 
 Column  :  Supelco LC8 analytical column 
 Mobile Phase  : Phosphate buffer pH 6.0 : methanol : acetonitrile      
        [63 : 21.5 : 15.5] 
 Flow Rate  :  1.0 mL/min 
 Detector  :  UV detection at 280 nm 
 
72. Van Heeswijk R P, et al., (1998) [91] have described a simple and rapid high 
performance liquid chromatographic method for the quantification 
of nevirapine in human plasma. The analyte was separated from endogenous 
compounds by isocratic reverse phase, ion pair and high performance liquid 
chromatography with ultraviolet detection at 282 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
4. AIM AND PLAN OF WORK 
 
DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR 
THE ASSAY OF NEVIRAPINE AND ITS RELATED SUBSTANCES IN 
TABLET DOSAGE FORM 
 
 From the literature survey, it was found that there are some analytical methods 
reported for nevirapine assay and fewer methods for the determination of impurities 
by RP-HPLC in pharmaceutical dosage forms. Nevirapine is increasingly finding use 
in treatment of anti-HIV as well as in combination therapy. So there is not only need 
to develop a newer analytical method for the estimation of nevirapine, but also to 
identify and quantify its process related impurities and its degradants. 
 
The present work is aimed at  
¾ Method development (By reverse phase HPLC). 
¾ Validation of the developed method (By using following parameters). 
a. Accuracy 
b. Precision 
c. Linearity and Range 
d. Limit of detection 
e. Limit of quantification 
f. Specificity 
g. Robustness 
h. Ruggedness 
i. System suitability studies 
j. Solution stability and filter study 
  
 
 
 
 
 
 
5. INSTRUMENTS AND MATERIALS 
 
 The following instruments and materials required for analytical method 
development and validation process of assay and related substances of nevirapine in 
tablet dosage form. 
 
Instrument used:  
• Waters separation module No. 2695, with PDA detector 2998 
• EMPOWER ver.02 software  
 
Reagents used: 
1. Monobasic ammonium phosphate  : Merck - AR grade 
2. Acetonitrile     : Merck - HPLC grade  
3. Water      : Millipore - Milli-Q grade 
4. Sodium hydroxide    : Merck - AR grade  
5. Ethanol      : Fischer scientific - AR grade 
 
Standards and samples 
Table No: 4 List of standards and sample 
Standard / Sample / Impurity 
Name Source 
Potency / 
Purity (%) 
Nevirapine USP RS USP 99.7 
Nevirapine Related Compound B USP 100.0 
Nevirapine Related Compound A USP 100.0 
Nevirapine Impurity C LGC 99.4 
Nevirapine USP Zhejiang HuahaiPharmaceutical NA 
Nevirapine Tablets USP 200 mg Edict pharma NA 
Nevirapine Tablets USP 200 mg 
placebo Edict pharma NA 
Nevirapine for peak identification 
CRS Edict Pharma NA 
 
 
SUMMARY AND CONCLUSION 
 
 Nevirapine is an anti-HIV of the non-nucleoside reverse transcriptase inhibitor 
(NNRTI). It is more potent than zidovudine on HIV-1, but do not inhibit HIV-2. Viral 
resistance to these drugs develops by point mutation and cross resistance is common. 
 
 Literature reports some UV-visible spectrophotometric, RP-HPLC methods 
for the quantification of the nevirapine in bulk drugs and formulations. But only few 
methods are available for determination of related substances and degradants. The 
chromatographic conditions were optimised for assay as well as related substances 
and the parameters are, 
 
Mobile phase   : Monobasic ammonium phosphate  
        buffer pH 5.0: ACN [80 : 20] 
Column    : Discovery Amide C16, 150 × 4.6, 5 µm 
Flow rate   : 1 mL/ min 
Column temperature  : 35 ºC 
Sample temperature  : 25 ºC 
Injection volume   : 25 µL 
Run time    : 25 mins 
Retention time    : 7.0 mins 
Wavelength    : 220 nm 
 
 The linear response was obtained with acceptable correlation co-efficient. No 
significant interference seen in specificity study. The method was fully validated for 
both assay of nevirapine and related substances with the precision, specificity/forced 
degradation study, accuracy, linearity, ruggedness, robustness, solution stability and 
filter study. 
 
 The values obtained for nevirapine, related compound A, B and impurity C 
was within the acceptance criteria. Hence the findings indicate that the developed 
method is precise, specific, accurate, linear, robust and rugged. This method can be 
used for the routine analysis of nevirapine and its related substances in tablet dosage 
form. 
